PREVENTION OF FEBRILE NEUTROPENIA
For initial authorization: 1. Member is 18 years of age or older with a non-myeloid malignancy; AND 2. Member must have tried and failed treatment with Zarxio; AND 3. Medication will not be administered within 24 hours of myelosuppressive chemotherapy and will be administered for at least 5 days until neutrophil recovery (ANC ≥1,000/mm 3 ) up to a maximum of 14 days; AND 4. Chart notes with length of chemotherapy cycle, the days of the cycle on which chemotherapy will be administered, and the day of the cycle on which Granix will be administered, are submitted with prior authorization request; AND 5. Member has a documented history of febrile neutropenia following a previous course of chemotherapy and is receiving myelosuppressive chemotherapy; OR 6. Member is receiving myelosuppressive anti-cancer drugs associated with a high risk (>20%, see Appendix for description) for incidence of febrile neutropenia; OR 7. Member is receiving myelosuppressive anti-cancer drugs associated with at intermediate risk If member meets all the requirements listed above, the medication will be approved for 6 months. For reauthorization: 1. Member must be in compliance with all other initial criteria; AND 2. Chart notes have been provided that show the member is stable or has shown improvement on Granix therapy.
If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months. 
